Key Highlights

  • Cadrenal Therapeutics shares settled up about 16%, near $1.78, versus Friday's $1.54, after trading as high as the $2.20s.
  • The company reported a constructive FDA Type D meeting, held July 28, on the Phase 3 plan for CAD-1005.
  • CAD-1005 is a first-in-class 12-LOX inhibitor being developed for heparin-induced thrombocytopenia (HIT).
  • The FDA aligned on protocol and statistics, including an optimized primary endpoint definition.

Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) shares settled up about 16%, near $1.78, versus Friday's $1.54, after trading as high as the $2.20s on heavy Volume following news of a constructive FDA Type D meeting held July 28 on the Phase 3 plan for CAD-1005.

What Happened

CAD-1005, a first-in-class 12-LOX inhibitor, is being developed for heparin-induced thrombocytopenia, a rare hospital condition in which heparin triggers antibodies and clotting. The FDA aligned with the company on protocol and statistics, including an optimized definition of worsening HIT for the primary endpoint, measuring progression of thrombotic events through Day 14 or discharge, in a placebo-controlled design with both arms on standard anticoagulation.

Cadrenal cites about 50,000 confirmed U.S. acute HIT cases annually and has outlined a potential peak-sales estimate near $2 billion, though that figure remains a projection rather than a forecast.

Market Reaction

Shares rose as investors responded to the regulatory clarity following Phase 2 data that had already shown a reduction in thrombotic events, though the company remains a micro-cap with limited cash, reported at about $4.2 million in early August.

Outlook

Cadrenal's ongoing partnering process, alongside its cash position, is likely to determine whether the Phase 3 trial in this acute orphan indication can move forward on the timeline the FDA discussion supports.